Disabling pansclerotic
morphea of childhood (
DPMC) is a rare subtype of juvenile
localized scleroderma (JLS) characterized by pansclerosis mainly affecting children under the age of 14. This aggressive disease has a poor prognosis due to the rapid progression of deep musculoskeletal
atrophy resulting in cutaneous ulceration and severe joint
contractures. We describe the challenges in treating a previously well 5-year-old male who has refractory symptoms of
DPMC. Over the 29 months, since his initial presentation, we trialed over ten
therapies. There was subjective improvement with
prednisolone and
mycophenolate mofetil (MMF). However, other
therapies including biologics and
tyrosine kinase inhibitors (TKI) were ineffective. The patient has been referred for hematopoietic stem cell transplant given ongoing
disease progression. We conducted a literature search focusing on English articles with keywords including
DPMC. Publications with limited information or describing cases aged 20 and above were excluded. Thirty-seven case reports were identified and the reported treatments were evaluated.
Methotrexate and
corticosteroids have been the most commonly utilized. MMF has been anecdotally effective. Biologics, TKI, and
Janus kinase inhibitors lack evidence in
DPMC, but have had demonstrated efficacy in similar pathologies including
systemic sclerosis, and, thus, have been used for
DPMC.
Phototherapy has been documented to be reducing skin thickness and stiffness of plaques. Eventually, most children require multi-modal and high-dose immunosuppressive therapies to reduce the
inflammation inflicted by the disease. Long-term
antibiotics and
nutritional support are important in the ongoing care of these patients.